IP Library Granted Patent US 7,702,386
Granted Patent B2
US 7,702,386 · App. 11/657,877 · Granted Apr 20, 2010

Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes

Assignee: Leptos Biomedical, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,702,386
App. No.
11/657,877
Granted
Apr 20, 2010
Kind
B2
Abstract

The disclosure provides a description of a tissue modulation device, for treating at least one of obesity, metabolic syndrome, and Type 2 diabetes in a patient. In some embodiments, the device includes a storage module having computer-readable instructions for delivering an electrical stimulation pattern to a splanchnic nerve of the patient. The stimulation pattern includes at least one on-time. The on-time includes at least one of a suprathreshold period and a subthreshold period. The splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, the lesser splanchnic nerve, and the least splanchnic nerve. The pattern is effective to ameliorate at least one attendant condition of obesity, metabolic syndrome, and Type 2 diabetes in the patient. The attendant condition includes dyslipidemia, hypertension, hyperinsulinemia, hyperglycemia, and/or insulin resistance.

Claims (97)

1. A method, for treating at least one of obesity, Type 2 diabetes, and metabolic syndrome in a patient, comprising:

providing a pulse generator, the pulse generator having a programmable stimulation pattern configured to deliver energy to an at least one nerve fiber group in a splanchnic nerve with a signal-on time that comprises a subthreshold period and a suprathreshold period and wherein the stimulation pattern comprises a frequency, a pulse width and a current, wherein the frequency is between about 0.1 Hz and 500 Hz, the pulse width is between about 100 microseconds and about 1 millisecond, and the current is between about 0.1 mA and about 10 mA;

electrically stimulating the nerve fiber group during the subthreshold period, wherein the subthreshold period comprises a period in which the energy delivered to the nerve fiber group is below the threshold for exciting the nerve fiber group;

electrically activating the nerve fiber group during the suprathreshold period, wherein the suprathreshold period comprises a period in which the energy delivered to the nerve fiber group meets or exceeds a threshold for exciting the nerve fiber group;

and wherein the stimulation pattern is configured to ameliorate or eliminate the at least one of obesity, metabolic syndrome, and Type 2 diabetes in the patient.

2. The method of claim 1 , further comprising programming the stimulation pattern so as to keep the patient's blood pressure within safe limits.

3. The method of claim 1 , wherein the suprathreshold period comprises a frequency that is less than the subthreshold period.

4. The method of claim 1 , further comprising selecting a patient with a waistline of greater than 35 inches.

5. The method of claim 1 , wherein the programmable stimulation pattern comprises the signal-on time and a signal-off time

wherein the signal-off time is no less than the signal-on time.

6. The method of claim 1 , wherein the stimulation pattern comprises a substantially continuous signal-on time, wherein the signal-on time is comprised of at least one suprathreshold period and at least one subthreshold period.

7. The method of claim 1 , wherein the subthreshold period is greater than the suprathreshold period.

8. The method of claim 1 , wherein the suprathreshold period is greater than the subthreshold period.

9. The method of claim 1 , wherein the step of electrically activating the nerve group comprises selectively activating an A fiber group, a B fiber group, a C fiber group or combinations thereof.

10. The method of claim 1 , wherein the programmable stimulation pattern comprises an intermittent electrical signal, comprising a frequency, a pulse width and a current, wherein the intermittent signal comprises a stimulation time period and a no stimulation time period and wherein the stimulation time period comprises the signal-on time and a signal-off time and wherein the intermittent electrical signal changes frequently enough and substantially enough to prevent compensation.

11. The method of claim 10 , wherein the subthreshold period comprises a current and the current increases after the signal-off time.

12. The method of claim 10 , wherein the suprathreshold current increases after the signal-off time.

13. The method of claim 10 , wherein the subthreshold current decreases after the signal-off time.

14. The method of claim 10 , wherein the suprathreshold current decreases after the signal-off time.

15. The method of claim 1 , wherein the suprathreshold period comprises a pulse width and the subthreshold period comprises a pulse width and wherein the suprathreshold pulse width is greater than the subthreshold pulse width.

16. The method of claim 1 , wherein the patient comprises lean muscle mass and wherein the lean muscle mass is maintained.

17. The method of claim 1 , wherein the patient comprises at least one attendant condition selected from the group consisting of insulin resistance, hyperglycemia, dyslipidemia, hypertension, and hyperinsulinemia.

18. The method of claim 17 , further comprising selecting a patient with insulin resistance.

19. The method of claim 17 , further comprising selecting a patient with hyperglycemia.

20. The method of claim 17 , further comprising selecting a patient with dyslipidemia.

21. The method of claim 20 , wherein the dyslipidemia comprises decreased HDL.

22. The method of claim 20 , wherein the dyslipidemia comprises elevated triglycerides.

23. The method of claim 20 , wherein the dyslipidemia comprises elevated LDL.

24. The method of claim 17 , further comprising selecting a patient with hypertension.

25. The method of claim 17 , further comprising selecting a patient with hyperinsulinemia.

26. The method of claim 1 , wherein the suprathreshold period comprises a frequency and wherein the frequency is less than 10 Hz.

27. The method of claim 1 , wherein the signal-on time comprises at least two subthreshold periods and at least one suprathreshold period.

28. The method of claim 1 , where in the splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, lessor splanchnic nerve and least splanchnic nerve.

29. A method of treating at least one of obesity, type 2 diabetes, and metabolic syndrome comprising:

providing a pulse generator, the pulse generator having a programmable stimulation pattern configured to deliver energy to a C fiber group in a splanchnic nerve with a signal-on time that comprises a subthreshold period and a suprathreshold period and wherein the stimulation pattern comprises a frequency, a pulse width and a current, wherein the frequency is between about 0.1 Hz and 500 Hz, the pulse width is between about 100 microseconds and about 1 millisecond, and the current is between about 0.1 mA and about 10 mA;

electrically stimulating the C fiber group during the subthreshold period,

electrically stimulating the C fiber group during the subthreshold period, wherein the subthreshold period comprises a period in which the energy delivered to the C fiber group is below the threshold for exciting the C fiber group;

electrically activating the C fiber group during the suprathreshold period, wherein the suprathreshold period comprises a period in which the energy delivered to the C fiber group meets or exceeds a threshold for exciting the C fiber group;

and wherein the stimulation pattern is configured to ameliorate or eliminate the at least one of obesity, metabolic syndrome, and Type 2 diabetes in the patient.

30. The method of claim 29 , wherein the signal-on time comprises at least two subthreshold periods and at least one suprathreshold period.

31. The method of claim 29 , further comprising programming the stimulation pattern so as to keep the patient's blood pressure within safe limits.

32. The method of claim 29 , wherein the suprathreshold period comprises a frequency that is less than the subthreshold period.

33. The method of claim 29 , further comprising selecting a patient with a waistline of greater than 35 inches.

34. The method of claim 29 , wherein the programmable stimulation pattern comprises the signal-on time and a signal-off time, wherein the signal-off time is no less than the signal-on time.

35. The method of claim 29 , wherein the stimulation pattern comprises a substantially continuous signal-on time, wherein the signal-on time is comprised of at least one suprathreshold period and at least one subthreshold period.

36. The method of claim 29 , wherein the subthreshold period is greater than the suprathreshold period.

37. The method of claim 29 , wherein the suprathreshold period is greater than the subthreshold period.

38. The method of claim 29 , wherein the programmable stimulation pattern comprises an intermittent electrical signal, comprising a frequency, a pulse width and a current, wherein the intermittent signal comprises a stimulation time period and a no stimulation time period and wherein the stimulation time period comprises the signal-on time and a signal-off time and wherein the intermittent electrical signal changes frequently enough and substantially enough to prevent compensation.

39. The method of claim 29 , wherein the subthreshold period comprises a current and the current increases after the signal-off time.

40. The method of claim 29 , wherein the suprathreshold current increases after the signal-off time.

41. The method of claim 29 , wherein the subthreshold current decreases after the signal-off time.

42. The method of claim 29 , wherein the suprathreshold current decreases after the signal-off time.

43. The method of claim 29 , wherein the suprathreshold period comprises a pulse width and the subthreshold period comprises a pulse width and wherein the suprathreshold pulse width is greater than the subthreshold pulse width.

44. The method of claim 29 , wherein the patient comprises lean muscle mass and wherein the lean muscle mass is maintained.

45. The method of claim 29 , wherein the patient comprises at least one attendant condition selected from the group consisting of insulin resistance, hyperglycemia, dyslipidemia, hypertension, and hyperinsulinemia.

46. The method of claim 45 , further comprising selecting a patient with insulin resistance.

47. The method of claim 45 , further comprising selecting a patient with hyperglycemia.

48. The method of claim 45 , further comprising selecting a patient with dyslipidemia.

49. The method of claim 48 , wherein the dyslipidemia comprises decreased HDL.

50. The method of claim 48 , wherein the dyslipidemia comprises elevated triglycerides.

51. The method of claim 48 , wherein the dyslipidemia comprises elevated LDL.

52. The method of claim 45 , further comprising selecting a patient with hypertension.

53. The method of claim 45 , further comprising selecting a patient with hyperinsulinemia.

54. The method of claim 29 , wherein the suprathreshold period comprises a frequency and wherein the frequency is less than 10 Hz.

55. The method of claim 29 , wherein the subthreshold period comprises a current and the current increases after the signal-off time.

56. The method of claim 29 , where in the splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, lessor splanchnic nerve and least splanchnic nerve.

57. A method of treating at least one of obesity, type 2 diabetes, and metabolic syndrome comprising:

providing a pulse generator, the pulse generator having a programmable stimulation pattern configured to deliver energy to a B fiber group in a splanchnic nerve with a signal-on time that comprises a subthreshold period and a suprathreshold period and wherein the stimulation pattern comprises a frequency, a pulse width and a current, wherein the frequency is between about 0.1 Hz and 500 Hz, the pulse width is between about 100 microseconds and about 1 millisecond, and the current is between about 0.1 mA and about 10 mA;

electrically stimulating the B fiber group during the subthreshold period,

electrically stimulating the B fiber group during the subthreshold period, wherein the subthreshold period comprises a period in which the energy delivered to the B fiber group is below the threshold for exciting the B fiber group;

electrically activating the B fiber group during the suprathreshold period, wherein the suprathreshold period comprises a period in which the energy delivered to the B fiber group meets or exceeds a threshold for exciting the B fiber group;

and wherein the stimulation pattern is configured to ameliorate or eliminate the at least one of obesity, metabolic syndrome, and Type 2 diabetes in the patient.

58. The method of claim 57 , wherein the signal-on time comprises at least two subthreshold periods and at least one suprathreshold period.

59. The method of claim 57 , further comprising programming the stimulation pattern so as to keep the patient's blood pressure within safe limits.

60. The method of claim 57 , wherein the suprathreshold period comprises a frequency that is less than the subthreshold period.

61. The method of claim 57 , further comprising selecting a patient with a waistline of greater than 35 inches.

62. The method of claim 57 , wherein the programmable stimulation pattern comprises the signal-on time and a signal-off time, wherein the signal-off time is no less than the signal-on time.

63. The method of claim 57 , wherein the stimulation pattern comprises a substantially continuous signal-on time, wherein the signal-on time is comprised of at least one suprathreshold period and at least one subthreshold period.

64. The method of claim 57 , wherein the subthreshold period is greater than the suprathreshold period.

65. The method of claim 57 , wherein the suprathreshold period is greater than the subthreshold period.

66. The method of claim 57 , wherein the programmable stimulation pattern comprises an intermittent electrical signal, comprising a frequency, a pulse width and a current, wherein the intermittent signal comprises a stimulation time period and a no stimulation time period and wherein the stimulation time period comprises the signal-on time and a signal-off time and wherein the intermittent electrical signal changes frequently enough and substantially enough to prevent compensation.

67. The method of claim 57 , wherein the suprathreshold current increases after the signal-off time.

68. The method of claim 57 , wherein the subthreshold current decreases after the signal-off time.

69. The method of claim 57 , wherein the suprathreshold current decreases after the signal-off time.

70. The method of claim 57 , wherein the suprathreshold period comprises a pulse width and the subthreshold period comprises a pulse width and wherein the suprathreshold pulse width is greater than the subthreshold pulse width.

71. The method of claim 57 , wherein the patient comprises lean muscle mass and wherein the lean muscle mass is maintained.

72. The method of claim 57 , wherein the patient comprises at least one attendant condition selected from the group consisting of insulin resistance, hyperglycemia, dyslipidemia, hypertension, and hyperinsulinemia.

73. The method of claim 72 , further comprising selecting a patient with insulin resistance.

74. The method of claim 72 , further comprising selecting a patient with hyperglycemia.

75. The method of claim 72 , further comprising selecting a patient with dyslipidemia.

76. The method of claim 75 , wherein the dyslipidemia comprises decreased HDL.

77. The method of claim 75 , wherein the dyslipidemia comprises elevated triglycerides.

78. The method of claim 75 , wherein the dyslipidemia comprises elevated LDL.

79. The method of claim 72 , further comprising selecting a patient with hypertension.

80. The method of claim 72 , further comprising selecting a patient with hyperinsulinemia.

81. The method of claim 57 , wherein the suprathreshold period comprises a frequency and wherein the frequency is less than 10 Hz.

82. The method of claim 57 , where in the splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, lessor splanchnic nerve and least splanchnic nerve.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2010
From: LEPTOS BIOMEDICAL INC.
To: ADVANCED NEUROMODULATION SYSTEMS, INC. D/B/A ST. JUDE MEDICAL NEUROMODULATION DIVISION
Reel/Frame 024369/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2007
From: DOBAK, JOHN D.; NEISZ, HANS
To: LEPTOS BIOMEDICAL, INC.
Reel/Frame 019095/0406 →
Continuity (17)
Continuation In Part 1133838800 · Jan 24, 2006
Continuation In Part 1092073400 · Aug 18, 2004
Continuation In Part 1078572600 · Feb 24, 2004
Continuation In Part 1027243000 · Oct 16, 2002
Continuation In Part 1024361200 · Sep 13, 2002
Provisional Application 6049643700 · Aug 20, 2003
Provisional Application 6047993300 · Jun 19, 2003
Provisional Application 6046689000 · Apr 30, 2003
Provisional Application 6046680500 · Apr 30, 2003
Provisional Application 6045236100 · Mar 5, 2003
Provisional Application 6045053400 · Feb 25, 2003
Provisional Application 6038669900 · Jun 10, 2002
Provisional Application 6038421900 · May 30, 2002
Provisional Application 6037960500 · May 10, 2002
Provisional Application 6037031100 · Apr 5, 2002
Provisional Application 6036675000 · Mar 22, 2002
Related Publication 20070203521A1 · Aug 30, 2007